Skip to content

Counterconditioning as treatment for chronic pain symptoms: a pilot study

Counterconditioning as treatment for chronic pain symptoms: a pilot study - Counterconditioning as treatment for pain

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON55456
Enrollment
36
Registered
2019-10-11
Start date
2020-01-09
Completion date
Unknown
Last updated
2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fibromyalgie chronic widespread pain Fibromyalgia

Interventions

Counterconditioning methods will be used for desensitization of pain symptoms in the intervention group. Participants in the intervention group will participate in a conditioning procedure once, in

Sponsors

Universiteit Leiden
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Diagnosis of fibromyalgia (provided by GP or medical specialist) Current pain symptoms because of fibromyalgia >= 18 years old female Good understanding of written and spoken Dutch

Exclusion criteria

Exclusion criteria: Physical conditions other than fibromyalgia explaining pain symptoms; Psychiatric conditions not related to the fibromyalgia symptoms (e.g., schizophrenia); Pregnancy or lactation; Refusal to remove artificial nails, nail polish, or any other substance covering the thumbnail; Having metal-containing implants in the non-dominant arm (including non-removable piercings); Carrying a pacemaker or implanted pumps; Injuries/open wounds on the non-dominant arm Not being able to clearly distinguish between three different pressure pain intensities during testing

Design outcomes

Primary

MeasureTime frame
The main study parameter will be the feasibility of the counterconditioning intervention. This will be done by looking at the drop-out rate, by measuring participant*s satisfaction with the intervention; by examing what, according to the participants, is causing the possible increase and reduction of experimentally evoked pressure pain in the test phase of (counter)conditioning (e.g., the TENS device, the placebo or nocebo effect); by exploring the amount of experimentally-evoked pressure pain reported during the test phase of counterconditioning, whether this reduces over time, as well as the speed of this reduction.

Secondary

MeasureTime frame
Not applicable.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)